FINHUB Insights

AMGN · Q1 FY26 · Jan 1 – Mar 31, 2026

Amgen Q1 FY26: where the revenue came from and where it went

Amgen Q1 FY26: revenue $8.6B (+6% year over year). Net profit $1.8B. Largest cohort Other $3.6B. The whole income statement as a sankey diagram from the SEC filing.

Period
Jan 1 – Mar 31, 2026
Reported
May 1, 2026 10-Q
Sankey diagram of Amgen's income statement for Q1 FY26: revenue of $8.62 billion splits into segments and flows out into costs, taxes and net profit.

Tap the diagram to enlarge · figures in billions of dollars

Revenue$8.62B +6% year over year
Gross profit$5.87B 68% margin
Operating profit$2.67B 31% margin
Net profit$1.82B 21% margin

The numbers

All figures in billions of U.S. dollars, for Q1 FY26 (period ends Mar 31, 2026).
ItemValueShare of revenueYear over year
Revenue 8.62 100% +6%
Other 3.59 42%
Other Products 1.53 18% +4%
Repathaevolocumab 0.88 10% +34%
Prolia 0.73 8% −34%
EVENITY 0.56 7% +27%
TEPEZZA 0.49 6% +29%
Otezla 0.43 5% −1%
BLINCYTO 0.42 5% +12%
Cost of revenue−2.7432%
Gross profit5.8768% margin+5pp
SG&A−1.6019%−2pp
Other−1.6119%+0pp
Operating profit2.6731% margin+16pp
Tax−0.27
Interest & other costs−0.58
Net profit1.8221%+0pp
Filing on EDGAR More quarters of AMGN

Source of the numbers: structured XBRL data from the filing (10-Q). The diagram is generated automatically and checked against EDGAR before release. How we calculate it → About and methodology.

Older quarters